细胞疗法在肝脏疾病临床治疗中的应用及展望

王贵强

doi:10.3969/j.issn.1001-5256.2023.05.001

细胞疗法在肝脏疾病临床治疗中的应用及展望

DOI: 10.3969/j.issn.1001-5256.2023.05.001

王贵强^, ,

北京大学第一医院感染疾病科，北京 100034

利益冲突声明：本文不存在任何利益冲突。

详细信息

通信作者:
王贵强，john131212@sina.com (ORCID：0000-0003-0515-7974)

计量
- 文章访问数: 467
- HTML全文浏览量: 70
- PDF下载量: 177
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-14
- 录用日期: 2023-04-12
- 出版日期: 2023-05-20

Application and prospect of cell therapy in clinical treatment of liver diseases

Guiqiang WANG^{,
,}

Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

More Information

Corresponding author: WANG Guiqiang, john131212@sina.com (ORCID: 0000-0003-0515-7974)

摘要

摘要: 细胞疗法是区别于传统药物的新兴疗法，其中免疫细胞和间充质干细胞是目前治疗肝脏疾病最有前景的两类细胞，其展现的治疗效果已经初见成效。本文对肝脏疾病领域相关的细胞疗法进展进行总结，分析不同细胞疗法的挑战和应对策略，并对细胞疗法在肝脏相关疾病中的应用前景进行展望。
- 肝疾病 /
- 细胞疗法 /
- 间充质干细胞 /
- 过继细胞疗法
Abstract: Cell therapy is an emerging therapy different from traditional drug therapy, among which immune cells and mesenchymal stem cells are the two types of most promising cells in the treatment of liver diseases at present, and preliminary results have been achieved for their therapeutic effects. This article summarizes the advances in cell therapy in the field of liver diseases, analyzes the challenges and coping strategies of different cell therapies, and discusses the application prospects of cell therapy in liver-related diseases.
- Liver Diseases /
- Cell Therapy /
- Mesenchymal Stem Cells /
- Adoptive Cell Therapy

HTML全文

参考文献(13)

[1]	SANGRO B, SAROBE P, HERVÁS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 525-543. DOI: 10.1038/s41575-021-00438-0.
[2]	CREELAN BC, WANG C, TEER JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial[J]. Nat Med, 2021, 27(8): 1410-1418. DOI: 10.1038/s41591-021-01462-y.
[3]	HUANG H, NIE CP, LIU XF, et al. Phase Ⅰ study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer[J]. J Clin Invest, 2022, 132(15): e157726. DOI: 10.1172/JCI157726.
[4]	KRISTENSEN NP, HEEKE C, TVINGSHOLM SA, et al. Neoantigen-reactive CD8⁺ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma[J]. J Clin Invest, 2022, 132(2): e150535. DOI: 10.1172/JCI150535.
[5]	JIANG SS, TANG Y, ZHANG YJ, et al. A phase Ⅰ clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma[J]. Oncotarget, 2015, 6(38): 41339-41349. DOI: 10.18632/oncotarget.5463.
[6]	WOLF NK, KISSIOV DU, RAULET DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy[J]. Nat Rev Immunol, 2023, 23(2): 90-105. DOI: 10.1038/s41577-022-00732-1.
[7]	HOOGSTAD-VAN EVERT J, BEKKERS R, OTTEVANGER N, et al. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase Ⅰ study)[J]. Medicine (Baltimore), 2019, 98(5): e14290. DOI: 10.1097/MD.0000000000014290.
[8]	BAE WK, LEE BC, KIM HJ, et al. A phase Ⅰ study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma[J]. Front Immunol, 2022, 13: 879452. DOI: 10.3389/fimmu.2022.879452.
[9]	CICHOCKI F, VAN DER STEGEN S, MILLER JS. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies[J]. Blood, 2023, 141(8): 846-855. DOI: 10.1182/blood.2022016205.
[10]	SHI M, LI YY, XU RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial[J]. Hepatol Int, 2021, 15(6): 1431-1441. DOI: 10.1007/s12072-021-10199-2.
[11]	WANG L, LI J, LIU H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28 (Suppl 1): 85-92. DOI: 10.1111/jgh.12029.
[12]	SALAMA H, ZEKRI AR, MEDHAT E, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease[J]. Stem Cell Res Ther, 2014, 5(3): 70. DOI: 10.1186/scrt459.
[13]	ZHANG Y, ZHANG J, YI H, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase Ⅰ/Ⅱ randomized, open-label, controlled trial[J]. Stem Cell Res Ther, 2021, 12(1): 244. DOI: 10.1186/s13287-021-02246-4.